Clinical Trial Update: Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating rituximab for inducing remission in chronic inflammatory demyelinating polyneuropathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC) | Conditions: CIDP | Phase 3 | Status: RECRUITING